2017 Press Releases

Keyword Search
 
DateTitle  
27-Mar-2017ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer
Conference call and webcast on Tuesday, March 28th at 14:30 pm CET/08:30 am EDT Primary progression-free survival (PFS) and overall survival (OS) endpoints met in patients with low asparagine synthetase (ASNS) Statistically significant improvement of OS and PFS in the entire patient population LYON, France--(BUSINESS WIRE)--Mar. 27, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERY... 
 Printer Friendly Version
23-Mar-2017ERYTECH Collaborates with Fox Chase Cancer Center to Advance Its Platform in the Field of Rare Metabolic Disorders
LYON, France--(BUSINESS WIRE)--Mar. 23, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases, today announced that it has entered into a research collaboration with Fox Chase Cancer Center (FCCC) to advance the pre-clinical development of the Company’s erymethionase program for h... 
 Printer Friendly Version
20-Mar-2017ERYTECH Presents New Preclinical Anti-Tumor Data on Erymethionase at AACR 2017
LYON, France--(BUSINESS WIRE)--Mar. 20, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced the presentation of new anti-tumor data supporting the Company’s preclinical product e... 
 Printer Friendly Version
07-Mar-2017ERYTECH to Present Preclinical Results Supporting Immunotherapy Potential of ERYMMUNE Platform at Two Upcoming Medical Meetings
LYON, France--(BUSINESS WIRE)--Mar. 7, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY), a French clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced the presentation of encouraging preclinical data supporting the Company’s ERYMMUNE prog... 
 Printer Friendly Version
02-Mar-2017ERYTECH Provides Business Update and Reports Financial Results for Full Year 2016
Conference call and webcast on Friday, March 3rd at 15:00 pm CET/09:00 am EST Activities for resubmission of European Marketing Authorization Application (MAA) for eryaspase (GRASPA) in relapsed and refractory acute lymphoblastic leukemia (ALL)ongoing after withdrawal in November 2016; resubmission targeted in Q3 2017 Patient enrollment completed in Phase 2 study of eryaspase in pancreatic cancer; top-li... 
 Printer Friendly Version
28-Feb-2017ERYTECH to Hold Business Update and 2016 Financial Results Conference Call on March 3rd, 2017
LYON, France--(BUSINESS WIRE)--Feb. 28, 2017-- Regulatory News: ERYTECH (Paris:ERYP) (ADR:EYRYY) :, the clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it will release its financial results and business update for the year ended December 31, 2... 
 Printer Friendly Version
17-Jan-2017ERYTECH Presents New Preclinical Data on ERY-MET at the 2017 ASCO GI Symposium
LYON, France--(BUSINESS WIRE)--Jan. 17, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris - ERYP), the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs (the "Company"), today announced new data supporting the second Company’s product candidate ERY-MET will be presented at the 2017 Gastrointe... 
 Printer Friendly Version
06-Jan-2017Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – December 2016
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Jan. 6, 2017-- Regulatory News: Erytech Pharma (Paris:ERYP) (ADR:EYRYY): Listing market: Euronext Paris from Euronext Market segment : segment B ISIN Code : FR0011471135 website : www.erytech.com Date   ... 
 Printer Friendly Version